Paper Details

  1. Home
  2. Paper Details

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.

Author: BoyapatiRay K, ColombelJean-Frédéric, NguyenTran M, PalmelaCarolina, ParkerClaire E, SilverbergOrli M, TorresJoana, UpadhyayaSonam D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Crohn's disease (CD) is a chronic digestive condition that can cause significant health problems. While strong medications are recommended for people with severe CD, it's not clear if these medications can be safely stopped once symptoms improve. Stopping medications could reduce side effects and costs, but may lead to the disease returning, requiring additional treatments or surgery.
Paper Details　
Original Abstract of the Article :
Crohn's disease (CD) is a chronic, relapsing and remitting disease of the gastrointestinal tract that can cause significant morbidity and disability. Current treatment guidelines recommend early intervention with immunosuppressant or biological therapy in high-risk patients with a severe disease phe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494506/

データ提供：米国国立医学図書館（NLM）

Withdrawal of Immunosuppressant Therapy for Crohn's Disease

Crohn's disease (CD), a chronic inflammatory bowel disease, often requires long-term treatment with immunosuppressant or biologic therapies. This study explores the feasibility of withdrawing these therapies in patients with quiescent CD, examining the potential benefits and risks associated with this approach. The researchers delve into the complex considerations surrounding drug withdrawal, balancing the desire to reduce adverse events and healthcare costs against the potential for disease relapse and other negative outcomes.

Balancing Benefits and Risks in Crohn's Disease Management

The study highlights the complex and nuanced decision-making process involved in managing CD. While the potential benefits of withdrawing immunosuppressant and biologic therapies are undeniable, the risks of disease relapse and other adverse outcomes must be carefully considered. This research provides valuable insights into the complexities of managing CD and underscores the importance of individualized treatment plans tailored to the specific needs of each patient.

The Importance of Personalized Treatment in Crohn's Disease

Just as a camel adapts to the changing terrain of the desert, CD patients require personalized treatment approaches that evolve with their condition. This study underscores the importance of careful monitoring and individualized decision-making in managing CD. By embracing a personalized approach, we can optimize treatment outcomes and ensure the best possible quality of life for individuals living with this complex and challenging disease.

Dr. Camel's Conclusion

This study delves into the complexities of managing CD, exploring the potential benefits and risks of withdrawing immunosuppressant and biologic therapies. The research highlights the importance of personalized treatment plans and emphasizes the need for careful consideration of each patient's unique circumstances. This study provides valuable insights for clinicians and patients alike, fostering a more informed and collaborative approach to managing this challenging condition.

Date :
  1. Date Completed 2018-07-06
  2. Date Revised 2023-10-11
Further Info :

Pubmed ID

29756637

DOI: Digital Object Identifier

PMC6494506

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.